-transparent.png){kind=logo}
The ability of actinomycin D, a known antineoplastic agent, to affect NK1 NK2 and NK3 tachykinin (TK) receptor types was assessed on several in vitro bioassays. Actinomycin D was completely ineffective as a TK antagonist in the guinea-pig ileum longitudinal muscle (GPI) and on the rat portal vein (RPV) (two issues containing NK1, and NK3 TK receptors, respectively) while it was a weak competitive antagonist in the endothelium-denuded rabbit pulmonary artery (RPA) and in the hamster trachea (HT) (tissues containing the NK2A and NK2B receptor subtypes, respectively). Furthermore actinomycin D was able to displace [125I]-His-NKA from NK2 receptor sites of the rat small intestine smooth muscle membranes. Although actinomycin D is about 3 orders of magnitude weaker as an NK2 antagonist as compared to the most effective ligands available, it could represent a starting point in the development of non-peptidic NK2 receptor antagonists.
R Patacchini, and
M Astolfi, and
M C Brown, and
C A Maggi
January 1995,
European journal of pharmacology,
R Patacchini, and
M Astolfi, and
M C Brown, and
C A Maggi
November 2006,
European journal of pharmacology,
R Patacchini, and
M Astolfi, and
M C Brown, and
C A Maggi
July 1990,
British journal of pharmacology,
R Patacchini, and
M Astolfi, and
M C Brown, and
C A Maggi
September 2000,
Molecular pharmacology,
R Patacchini, and
M Astolfi, and
M C Brown, and
C A Maggi
June 2005,
European journal of pharmacology,
R Patacchini, and
M Astolfi, and
M C Brown, and
C A Maggi
January 1998,
European journal of pharmacology,
R Patacchini, and
M Astolfi, and
M C Brown, and
C A Maggi
November 1997,
Naunyn-Schmiedeberg's archives of pharmacology,
R Patacchini, and
M Astolfi, and
M C Brown, and
C A Maggi
December 1994,
Neuropeptides,
R Patacchini, and
M Astolfi, and
M C Brown, and
C A Maggi
November 2021,
Autonomic neuroscience : basic & clinical,
R Patacchini, and
M Astolfi, and
M C Brown, and
C A Maggi
February 1994,
Biochemical and biophysical research communications,
